Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 15, 2011

Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy

  • Enobia selected Lonza for the production of its bone-targeted enzyme-replacement therapy ENB-0040, under investigation for the treatment of hypophosphatasia (HPP). Lonza will provide process validation and commercial manufacturing at its large-scale biologics site in Portsmouth, NH, with an option to extend production to a second Lonza site.

    HPP is caused by a deficiency in the tissue nonspecific form of alkaline phosphatase (TNSALP), an enzyme that plays a key role in regulating bone mineralization. Without TNSALP, inorganic pyrophosphate accumulates extracellulary and inhibits skeletal mineralization, leading to rickets in pediatric patients or osteomalacia in adults. ENB-0040 is proposed to directly target functional alkaline phosphatase to the patient’s bones to help correct the enzyme deficiency.

    Enobia recently completed a Phase II juvenile study. It met the primary endpoint, demonstrating a statistically significant improvement in rickets when compared with historical matched cohort controls. Rickets, a softening and weakening of the bones, is often seen in children with HPP and can lead to fractures, pain, and deformity.

    The company previously reported the successful completion of a trial in infants. Participants reportedly continue to demonstrate functional and respiratory improvements in longer-term follow-up. A Phase II study in adolescents and adults with HPP is ongoing.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »